CEO Clips - Cannara Biotech Expands Cannabis Production with Mega Facilities

Cannara Biotech is building its strategy around those factors through two large cultivation facilities designed specifically for cannabis production.

CEO Clips - Cannara Biotech Expands Cannabis Production with Mega Facilities

Vertically integrated producer scales capacity to meet growing demand

How is Cannara Biotech scaling cannabis production in Canada?

Cannara Biotech operates two purpose-built cannabis cultivation facilities totaling more than 1.6 million square feet, allowing the company to grow up to 100 tonnes annually as market demand increases.

Cannabis production at scale requires infrastructure, consistency, and operational control, principles that Cannara Biotech has embedded into its strategy through two purpose-built cultivation facilities: a 1 million-square-foot site in Valleyfield and a 605,000-square-foot facility in Farnham, together forming one of the largest cultivation footprints among Canadian licensed producers.

Current output is approximately 50,000 kilograms of cannabis annually, with the ability to scale to 100,000 kilograms per year as additional cultivation zones are activated.

Cannara is also fully vertically integrated, meaning the company manages the entire process from cultivation through finished product manufacturing and distribution to it’s provincial government partners across Canada. This structure allows tighter control over product consistency, quality, and supply chain efficiency.

The company recently announced it’s uplisting to the TSX as a strategy to improve accessibility for investors and increase visibility in Canadian capital markets.

As Canada’s cannabis market matures, scale, efficiency, and brand consistency remain key competitive advantages for licensed producers.

To learn more about Cannara Biotech (TSX: LOVE, OTCQX: LOVFF), please click the request investor info button.

No items found.

You might also like

Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs
Life Sciences
August 28, 2026

Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs

Next-generation weight-management drugs face a simple challenge: effectiveness must be matched by tolerability.

This is some text inside of a div block.
Brompton LCS: How Can Investors Earn Monthly Income from Canadian Life Insurers?
Finance
August 27, 2026

Brompton LCS: How Can Investors Earn Monthly Income from Canadian Life Insurers?

This is some text inside of a div block.
Brompton Funds
ETFs
August 27, 2026

Brompton Funds: Enhanced Multi-Asset Income ETF - BMAX

BMAX is designed to provide attractive monthly distributions and the opportunity for capital appreciation by investing in a portfolio of Brompton ETFs and preferred shares.

This is some text inside of a div block.
Subscribe and receive the investor Info